Should diseases of the poor or of the rich be prioritised?

Both the Quality-Adjusted Life Year (QALY) or Disability-Adjusted Life Year (DALY), which are used by institutions like the National Institute for Health and Care Excellence (NICE) and the WHO to decide whether or not a medicine is cost-effective. But no measurement is perfect and it is possible to adjust them in order to fit the remuneration right model fairly and accommodate all scenarios, including rare diseases.